Generic Name: nelarabine
Drug Class: Chemotherapy Medications
Company: Novartis
Approval Status: Approved
Generic Version Available: No
Drug Indication
Arranon is a nucleoside inhibitor approved for refractory T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma.
General Info
Arranon is a defective DNA building block that halts cell replication. Studies showed it reduces the number of cancerous cells in people with certain types of T cell leukemia and lymphoma.
Dosage
Dosing Info:
Arranon is given as an intravenous infusion. It may be used by both adults and children.
Side Effects
Common side effects include nausea, diarrhea, vomiting, constipation, fatigue, fever, cough and shortness of breath. Arranon can cause depletion of red blood cells (anemia), white blood cells (neutropenia) and platelets (thrombocytopenia), which can lead to infections and easy bleeding. The Arranon label has a warning about severe neurological side effects including altered mental state, convulsions and peripheral nerve damage. Arranon may cause fetal harm if used during pregnancy.
For More Info: https://www.pharma.us.novartis.com/sites/www.pharma.us.novartis.com/files/arranon.pdf
Co-Pay Program Info: https://www.pharma.us.novartis.com/our-products/patient-assistance/patient-assistance-foundation-enrollment
Last Reviewed: November 29, 2018
